Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Veradigm stock (MDRX)

Buy Veradigm stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Veradigm is a health information services business based in the US. Veradigm shares (MDRX) are listed on the NASDAQ and all prices are listed in US Dollars. Veradigm employs 8,000 staff and has a trailing 12-month revenue of around $1.5 billion.

Our top picks for where to buy Veradigm stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Veradigm stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – MDRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Veradigm stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Veradigm stock price (NASDAQ: MDRX)

Use our graph to track the performance of MDRX stocks over time.

Veradigm shares at a glance

Information last updated 2024-07-14.
Latest market close$9.90
52-week range$5.01 - $14.09
50-day moving average $8.86
200-day moving average $9.81
Wall St. target price$11.40
PE ratio 11.4535
Dividend yield N/A (0%)
Earnings per share (TTM) $0.86

Is it a good time to buy Veradigm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Veradigm price performance over time

Historical closes compared with the close of $9.9 from 2024-07-19

1 week (2024-07-12) 0.51%
1 month (2024-06-21) 4.21%
3 months (2024-04-19) 30.26%
6 months (2024-01-19) 9.76%
1 year (2023-07-21) -26.12%
2 years (2022-07-21) -33.29%
3 years (2021-07-21) 17.44
5 years (2019-07-19) 10.95

Is Veradigm stock undervalued or overvalued?

Valuing Veradigm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veradigm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Veradigm's P/E ratio

Veradigm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Veradigm shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Veradigm's PEG ratio

Veradigm's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4237. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Veradigm's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Veradigm's EBITDA

Veradigm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $115.4 million.

The EBITDA is a measure of a Veradigm's overall financial performance and is widely used to measure a its profitability.

Veradigm financials

Revenue TTM $1.5 billion
Operating margin TTM 16.59%
Gross profit TTM $738.3 million
Return on assets TTM 2.16%
Return on equity TTM 8.93%
Profit margin 3.97%
Book value $10.77
Market Capitalization $1.1 billion

TTM: trailing 12 months

Veradigm share dividends

We're not expecting Veradigm to pay a dividend over the next 12 months.

Veradigm share price volatility

Over the last 12 months, Veradigm's shares have ranged in value from as little as $5.01 up to $14.09. A popular way to gauge a stock's volatility is its "beta".

MDRX.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veradigm's is 0.627. This would suggest that Veradigm's shares are less volatile than average (for this exchange).

Veradigm overview

Veradigm Inc. , a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc.

Frequently asked questions

What percentage of Veradigm is owned by insiders or institutions?
Currently 1.295% of Veradigm shares are held by insiders and 26.167% by institutions.
How many people work for Veradigm?
Latest data suggests 8,000 work at Veradigm.
When does the fiscal year end for Veradigm?
Veradigm's fiscal year ends in December.
Where is Veradigm based?
Veradigm's address is: 222 Merchandise Mart Plaza, Chicago, IL, United States, 60654
What is Veradigm's ISIN number?
Veradigm's international securities identification number is: US01988P1084
What is Veradigm's CUSIP number?
Veradigm's Committee on Uniform Securities Identification Procedures number is: 01988P108

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site